- EoE affects more than 450,000 people in the United States and has been identified by
the American Gastroenterological Association as rapidly increasing
in both incidence and prevalence
- Registration for the webinar now open to the public by visiting
EPRXNOV1524.TribePublic.com
VICTORIA, BC, Nov. 13,
2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc.
("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a
clinical-stage biotechnology company leveraging its proprietary
DiffuSphere™ technology designed to optimize drug delivery for
applications with significant unmet need, today announced that
Eupraxia's CEO, Dr. James A.
Helliwell, will present at a Tribe Public Webinar
Presentation and Q&A Event titled, "Eosinophilic Esophagitis:
The Emerging Digestive Disorder Frequently Misdiagnosed".
The event is scheduled to begin at 8:30
am PT / 11:30 am ET on Friday,
November 15, 2024.
To register to join the complimentary event, please visit Tribe
Public at:
EPRXNOV1524.TribePublic.com
Once registered, participants may begin forwarding their
questions for Dr. Helliwell to Tribe Public at
research@tribepublic.com, or share their questions via the ZOOM
chat feature during the event. Tribe Public's Managing Member,
John F. Heerdink, Jr., will host the
event and relay all questions to management.
About Eosinophilic Esophagitis
Eosinophilic Esophagitis ("EoE") is an inflammatory-mediated
disease in which white blood cells migrate into and become trapped
in the esophagus, creating pain and difficulty with swallowing
food. According to market research from Clearview Healthcare
Partners, EoE affects more than 450,000 people in the United States and has been identified by
the American Gastroenterological Association as rapidly increasing
in both incidence and prevalence. Impacts from both symptoms and
interventions frequently lead to mental health issues, compounding
the disease burden of EoE for both the healthcare system and the
individual.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company focused on
the development of locally delivered, extended-release products
that have the potential to address therapeutic areas with high
unmet medical need. DiffuSphere™, a proprietary, polymer-based
micro-sphere technology, is designed to facilitate targeted drug
delivery of both existing and novel drugs. The technology is
designed to support extended duration of effect and delivery of
drugs in a hyper-localized fashion, targeting only the tissues that
physicians are wanting to treat. We believe the potential for fewer
adverse events may be achieved through the precision targeting and
the stable and flat delivery of the active ingredient when using
the DiffuSphere™ technology, versus the peaks and troughs seen with
more traditional drug delivery methods. The precision of Eupraxia's
DiffuSphere™ technology platform has the potential to augment and
transform existing FDA-approved drugs to improve their safety,
tolerability, efficacy and duration of effect. The potential uses
in therapeutic areas may go beyond pain and inflammatory
gastrointestinal disease, where Eupraxia currently is developing
advanced treatments, to also be applicable in oncology, infectious
disease and other critical disease areas.
Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment
of EoE. EP-104GI is administered as an injection into the
esophageal wall, providing local delivery of drug. This is a unique
treatment approach for EoE. Eupraxia also recently completed a
Phase 2b clinical trial (SPRINGBOARD)
of EP-104IAR for the treatment of pain due to knee osteoarthritis.
The trial met its primary endpoint and three of the four secondary
endpoints. In addition, Eupraxia is developing a pipeline of later
and earlier-stage long-acting formulations. Potential pipeline
indications include candidates for other inflammatory joint
indications and oncology, each designed to improve on the activity
and tolerability of currently approved drugs. For further details
about Eupraxia, please visit the Company's website at:
www.eupraxiapharma.com.
About Tribe Public LLC
Tribe Public LLC is a San Francisco,
CA-based organization that hosts complimentary worldwide
webinar & in-person meeting events in the U.S. Tribe's
complimentary events focus on issues that the Tribe members care
about with an emphasis on hosting management teams from publicly
traded companies from all sectors & financial organizations
that are seeking to increase awareness of their products, progress
and plans. Tribe members primarily include Family Offices,
Portfolio Managers, Registered Investment Advisors, Accredited
Investors, Sell Side Analysts, and members of media. Tribe Members
are encouraged to express their interest in speakers they care
about and want to learn from at the Tribe Public website via the
Tribe's FREE "Wish List" process. Visit Tribe Public's Website to
learn more: http://www.tribepublic.com.
Notice Regarding Forward-looking Statements and
Information
This news release includes forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. Often, but not always, forward-looking information
can be identified by the use of words such as "plans", "is
expected", "expects", "suggests", "scheduled", "intends",
"contemplates", "anticipates", "believes", "proposes", "potential"
or variations (including negative and grammatical variations) of
such words and phrases, or state that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur
or be achieved. Forward-looking statements in this news release
include statements regarding Tribe Public's webinar event; the
Company's product candidates, including their expected benefits to
patients with respect to safety, tolerability, efficacy and
duration; the results gathered from studies and trials of
Eupraxia's product candidates; the potential for the Company's
technology to impact the drug delivery process; potential market
opportunity for the Company's products, and potential pipeline
indications. Such statements and information are based on the
current expectations of Eupraxia's management, and are based on
assumptions, including but not limited to: future research and
development plans for the Company proceeding substantially as
currently envisioned; industry growth trends, including with
respect to projected and actual industry sales; the Company's
ability to obtain positive results from the Company's research and
development activities, including clinical trials; and the
Company's ability to protect patents and proprietary rights.
Although Eupraxia's management believes that the assumptions
underlying these statements and information are reasonable, they
may prove to be incorrect. The forward-looking events and
circumstances discussed in this news release may not occur by
certain dates or at all and could differ materially as a result of
known and unknown risk factors and uncertainties affecting
Eupraxia, including, but not limited to: risks and uncertainties
related to the Company's limited operating history; the Company's
novel technology with uncertain market acceptance; if the Company
breaches any of the agreements under which it licenses rights to
its product candidates or technology from third parties, the
Company could lose license rights that are important to its
business; the Company's current license agreement may not provide
an adequate remedy for its breach by the licensor; the Company's
technology may not be successful for its intended use; the
Company's future technology will require regulatory approval, which
is costly and the Company may not be able to obtain it; the Company
may fail to obtain regulatory approvals or only obtain approvals
for limited uses or indications; the Company's clinical trials may
fail to demonstrate adequately the safety and efficacy of its
product candidates at any stage of clinical development; the
Company may be required to suspend or discontinue clinical trials
due to side effects or other safety risks; the Company completely
relies on third parties to provide supplies and inputs required for
its products and services; the Company relies on external contract
research organizations to provide clinical and non-clinical
research services; the Company may not be able to successfully
execute its business strategy; the Company will require additional
financing, which may not be available; any therapeutics the Company
develops will be subject to extensive, lengthy and uncertain
regulatory requirements, which could adversely affect the Company's
ability to obtain regulatory approval in a timely manner, or at
all; the impact of health pandemics or epidemics on the Company's
operations; the Company's restatement of its consolidated financial
statements, which may lead to additional risks and uncertainties,
including loss of investor confidence and negative impacts on the
Company's common share price; and other risks and uncertainties
described in more detail in Eupraxia's public filings on SEDAR+
(sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted
to identify important factors that could cause actual actions,
events or results to differ materially from those described in
forward-looking statements and information, there may be other
factors that cause actions, events or results to differ from those
anticipated, estimated or intended. No forward-looking statement or
information can be guaranteed. Except as required by applicable
securities laws, forward-looking statements and information speak
only as of the date on which they are made and Eupraxia undertakes
no obligation to publicly update or revise any forward-looking
statement or information, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-ceo-dr-james-helliwell-to-participate-in-webinar-event-eosinophilic-esophagitis-the-emerging-digestive-disorder-frequently-misdiagnosed-on-november-15-2024-302304796.html
SOURCE Eupraxia Pharmaceuticals Inc.